Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lcLNP anti-CD19 CAR mRNA
- Development stage
- Preclinical
- Lead developer
- NanoVation Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
lcLNP anti-CD19 CAR mRNA is an in vivo chimeric antigen receptor (CAR) therapy candidate developed by NanoVation Therapeutics in collaboration with the Fred Hutch Cancer Center. The therapy utilizes NanoVation's proprietary long-circulating lipid nanoparticle (lcLNP) platform to deliver mRNA encoding an anti-CD19 CAR directly to immune effector cells, including T cells and myeloid cells, following intravenous administration. Unlike conventional LNPs that are rapidly cleared by the liver, lcLNPs are engineered for extended circulation and enhanced biodistribution to extrahepatic lymphoid tissues such as the spleen and bone marrow. This approach facilitates the transient in vivo generation of CAR-expressing cells that can effectively deplete B cells, offering a potentially more accessible and scalable alternative to traditional ex vivo CAR-T cell therapies for the treatment of B-cell malignancies and autoimmune diseases like systemic lupus erythematosus (SLE).
- Other names
- long-circulating lipid nanoparticle anti-CD19 CAR mRNA
02
Targets
Beyond the preview
Go deeper on lcLNP anti-CD19 CAR mRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lcLNP anti-CD19 CAR mRNA.